Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00265655
Status:
COMPLETED
Last Update Posted:
2012-03-28
First Post:
2005-12-01
Brief Title:
Satraplatin for Patients With Metastatic Breast Cancer MBC
Sponsor:
Agennix
Organization:
Agennix
Study Overview
Official Title:
Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer MBC
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the objective response rate ORR of oral satraplatin in patients with Metastatic Breast Cancer
Detailed Description:
This is a Phase II open label nonrandomized study for patients with metastatic breast cancer
WHAT IS SATRAPLATIN
Satraplatin is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
WHAT IS SATRAPLATIN
Satraplatin is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None